<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788615</url>
  </required_header>
  <id_info>
    <org_study_id>COMB157G3301</org_study_id>
    <secondary_id>2020-004505-32</secondary_id>
    <nct_id>NCT04788615</nct_id>
  </id_info>
  <brief_title>Open Label Randomized Multicenter to Assess Efficacy &amp; Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS</brief_title>
  <acronym>STHENOS</acronym>
  <official_title>Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare ofatumumab vs. European approved platform first line&#xD;
      self-administered disease modifying therapy (DMT) in newly diagnosed MS patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized (1:1), open-label, rater-blind, multi-center, prospective,&#xD;
      parallel-arm, active comparator study which will consist of 15 months treatment period and a&#xD;
      6 months observational safety extension period in 236 total patients with early relapsing&#xD;
      multiple sclerosis (RMS) RMS patients are patients who are newly diagnosed or have never been&#xD;
      on active treatment at the time of study entry with ≤ 3 years from first MS symptoms.&#xD;
&#xD;
      There is a screening period and patients are randomized to either ofatumumab or first line&#xD;
      DMT at baseline. Patients will be treated until the end of study (EOS) or for a maximum&#xD;
      duration of 15 months. Patients who prematurely discontinue study drug or comparator will&#xD;
      have their end of treatment (EOT) visit and assessments at the time of discontinuation. After&#xD;
      ofatumumab or the standard of care comparator (DMT) discontinuation, patients may initiate&#xD;
      alternative MS therapy according to local standard of care, if clinically indicated.&#xD;
&#xD;
      Patients who for any reason withdraw from ofatumumab during treatment will be invited to&#xD;
      participate in the observational extension safety period for 6 months or until patient&#xD;
      re-starts MS treatment with a new DMT treatment. During this period, clinical efficacy after&#xD;
      ofatumumab withdrawal will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">September 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The independent EDSS (Expanded disability status scale) rater will be blind to the identity of the treatment throughout the study period. Patient MRI scans read by an independent central MRI reading center.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with no evidence of disease activity (NEDA-3)</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>NEDA-3 (yes/no) is defined as:&#xD;
Absence of confirmed clinical relapse&#xD;
Absence of new MRI activity (Gd+ T1 lesion or new/enlarged T2 lesion) with MRI re-baselined at Month 3&#xD;
Absence of 3-month confirmed disability worsening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>Baseline to 15months</time_frame>
    <description>Number of relapses will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate</measure>
    <time_frame>Baseline 15months</time_frame>
    <description>Annual relapse rate will be analyzed by treatment group using negative binomial regression model with log-link and patient's time in study will be used as an offset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of relapse-free patients and proportion of relapse free patients with MRI activity free</measure>
    <time_frame>Baseline, Month 3 9 and 15</time_frame>
    <description>Proportion of relapse-free patients and proportion of relapse-free patients with MRI activity free at Month 3, 9 and 15 will be summarized descriptively at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 3 month Confirmed Disability Worsening (CDW) and time to 6-month Confirmed Disability Worsening (CDW)</measure>
    <time_frame>Baseline, Month 3 and 6</time_frame>
    <description>Time to 3 month Confirmed Disability Worsening (CDW) and time to 6-month CDW will be assessed by EDSS (Expanded disability status scale) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expanded disability status scale (EDSS) from baseline to end of study</measure>
    <time_frame>Baseline, Month 15</time_frame>
    <description>Change in expanded disability status scale (EDSS) from baseline to end of study will be summarized descriptively based on the expanded disability status scale (EDSS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of disability-progression free patients at end of study</measure>
    <time_frame>Baseline, 15 month</time_frame>
    <description>Proportion of disability-progression free patients at end of study will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Gd+ T1 lesions of brain</measure>
    <time_frame>Baseline to 15 month</time_frame>
    <description>Number of Gd+ T1 lesions of brain will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of patients with Treatment emergent adverse events (TEAE) or adverse events reports until safety follow-up</measure>
    <time_frame>Base line to 15 month and 6 months safety follow-up</time_frame>
    <description>Adverse will be collected at each patients visit including any clinically significant safety assessments determined to be an adverse event by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Gd+ lesions of brain</measure>
    <time_frame>Baseline to 15 month</time_frame>
    <description>Volume of Gd+ lesions of brain will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new/enlarging T2 lesions of brain</measure>
    <time_frame>Baseline to 15 month</time_frame>
    <description>Number of new/enlarging T2 lesions of brain will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new enlarging T2 lesions of brain</measure>
    <time_frame>Baseline to 15 month</time_frame>
    <description>Volume of new enlarging T2 lesions of brain will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to first relapse</measure>
    <time_frame>Baseline to 15 month</time_frame>
    <description>Mean time to first relapse will be summarized descriptively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First line DMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glatiramer acetate minimum dose 20mg or maximum dose 40mg twice a day or three times a week or&#xD;
Interferon minimum dose 22µg or maximum dose of 0.25mg 3 times a week or once a week or Every second week depending on preparation or&#xD;
Teriflunomide 14 mg once a day or&#xD;
Dimethyl fumarate minimum dose of 240mg or maximum dose of 480mh twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>20mg Subcutaneous injection</description>
    <arm_group_label>ofatumumab</arm_group_label>
    <other_name>OMB157</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First line DMT</intervention_name>
    <description>any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Teriflunomide 14mg or Dimethyl fumarate 240mg or 480mg</description>
    <arm_group_label>First line DMT</arm_group_label>
    <other_name>Glatiramer acetate or Interferon or Teriflunomide or Dimethyl fumarate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male/female patients, 18 through 45 (inclusive) years of age.&#xD;
&#xD;
          2. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018).&#xD;
&#xD;
          3. Relapsing MS: relapsing-course (RMS), as defined by Lublin et al 2014.&#xD;
&#xD;
          4. Treatment Naïve patients, ≤ 3 years since first MS symptom.&#xD;
&#xD;
          5. Patient must be suitable to be treated with one of first line self-administered&#xD;
             DMT-physician's choice&#xD;
&#xD;
          6. EDSS score 0-3 (inclusive).&#xD;
&#xD;
          7. At least 1 relapse or or 1 Gd+ enhanced lesion on T1in the year prior to Screening.&#xD;
&#xD;
          8. Neurologically stable within 1 month prior to first study drug administration&#xD;
             Exclusion Criteria&#xD;
&#xD;
        1. Relapse between Screening and Baseline visits 2. Pregnancy or breastfeeding 3. Women of&#xD;
        childbearing potential defined as all women physiologically capable of becoming pregnant,&#xD;
        unless they are using highly effective methods of contraception 4. Patients with an active&#xD;
        chronic disease of the immune system other than MS or with immunodeficiency syndrome 5.&#xD;
        Patients with a chronic active infection, until the infection is resolved. Where local&#xD;
        regulation requires it, Sars-Cov-19 must be ruled out by the PCR test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gonesse</city>
        <zip>95500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westerstede/Oldenburg</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ofatumumab</keyword>
  <keyword>relapsing multiple sclerosis</keyword>
  <keyword>relapsing-remitting MS</keyword>
  <keyword>MS therapy</keyword>
  <keyword>RMS</keyword>
  <keyword>Relapsing MS</keyword>
  <keyword>Glatiramer acetate</keyword>
  <keyword>IFNβ-1b</keyword>
  <keyword>IFNβ-1a</keyword>
  <keyword>peg-IFNβ-1a</keyword>
  <keyword>Teriflunomide</keyword>
  <keyword>Dimethyl fumarate</keyword>
  <keyword>OMB157</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Teriflunomide</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

